Search

To reach World Health Organization elimination targets for hepatitis C, different strategies are needed to reach people who have not yet been diagnosed and treated. In the context of declining treatment initiation rates, innovation in service design and delivery is necessary: testing and treatment needs to be offered to people in non-traditional settings. The community corrections (probation and parole) population is larger than the prison population, which has high prevalence of hepatitis C and-in some countries-established diagnosis and treatment programs. In this Viewpoint we identify a gap in hepatitis C care for people under community correctional supervision, a group who have either never been imprisoned or need continuity of healthcare provided in prison. We propose that offering hepatitis C screening and treatment would benefit this population, and accelerate progress to hepatitis C elimination., Competing Interests: RW has received investigator-initiated funding from Gilead Sciences. YS is a co-investigator on investigator-initiated research grants from Gilead Sciences and AbbVie. MS has received investigator-initiated research grants from Abbvie and Gilead and consultancy from Gilead. AL has received investigator-initiated research grant support from Gilead Sciences and AbbVie. AJT has received consulting fees from Gilead, Abbvie, Roche Diagnostics, Assembly Biosciences, speaker fees from Gilead Sciences, Roche Diagnostics and investigator-initiated grants from Gilead Sciences. All other authors have no conflicts to declare., (© 2024 The Author(s).)